NIAID Commits $100 Million a Year to Pandemic Preparedness — and the First Awards Are Out

Seven research teams split across six universities just received some of the most strategically significant infectious-disease funding in years — and most of the grant-seeking world barely noticed. While headlines fixated on NIH budget fights and SBIR reauthorization drama, the National Institute of Allergy and Infectious Diseases quietly stood up a new network that could reshape how the United States prepares for the next pandemic.

The program is called ReVAMPP — Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness — and NIAID expects to commit roughly $100 million per year to fund it (Granted News). That is not a one-time infusion. It is a sustained, annual commitment designed to build institutional capacity that outlasts any single grant cycle.

The Prototype-Pathogen Bet

ReVAMPP's intellectual architecture rests on a concept that has been gaining traction in virology circles for years but has never been funded at this scale: the prototype-pathogen approach.

The logic is straightforward. Rather than waiting for a novel virus to emerge and then racing to develop countermeasures from scratch — the COVID-19 playbook — scientists study representative pathogens from virus families known to infect humans. The knowledge base built from those prototypes can then be rapidly adapted when a related pathogen jumps into the human population.

The network targets five virus families: Arenaviridae, Flaviviridae, Paramyxoviridae, Picornaviridae, and Togaviridae. These are not random selections. Each family contains viruses with documented pandemic or epidemic potential — from Lassa fever and dengue to Nipah and chikungunya. By building deep molecular and immunological understanding of prototype members in each family, the theory goes, researchers will be able to pivot countermeasure development in weeks rather than months when a cousin virus appears.

It is the difference between designing a car from raw ore every time and having a chassis, engine, and drivetrain on the shelf, ready for customization.

Who Won — and What Each Center Does

NIAID awarded seven U19 cooperative agreements to six institutions. The awards are structured as five-year grants, though funding for years four and five depends on milestone achievement, contribution to the network, and continued appropriations.

Albert Einstein College of Medicine received a center called PROVIDENT, led by Kartik Chandran. The team focuses on arenavirus and filovirus countermeasures — the same viral families responsible for Lassa fever and Ebola-like hemorrhagic fevers.

University of California, Irvine houses the Vaccines for Pandemic Preparedness Center under Louis Philip Felgner, a veteran of platform vaccine technology development. The center works across multiple virus families with an emphasis on rapid antigen design and immune profiling.

University of Texas Medical Branch (UTMB) in Galveston — home to one of the country's few Biosafety Level 4 laboratories — won a center targeting Paramyxoviridae and Bunyavirales, led by Thomas Geisbert. This is where Nipah virus research happens, in facilities built to handle the most dangerous pathogens on the planet.

University of Washington received a center focused on machine-learning-enabled vaccine design, led by Neil King. King's lab pioneered computational protein design for self-assembling nanoparticle vaccines — the same technology behind several next-generation COVID-19 vaccine candidates. Applying those tools across multiple virus families could dramatically compress the timeline from pathogen identification to clinical-grade immunogen.

Vanderbilt University Medical Center won a center covering bunyaviruses and picornaviruses under James Crowe Jr., whose lab has isolated thousands of human monoclonal antibodies against emerging viruses. The center pairs antibody discovery with vaccine development in a two-pronged approach.

Washington University in St. Louis received two awards — one targeting flaviviruses (dengue, Zika, and their relatives) under Michael Diamond, and another covering paramyxoviruses under Sean Whelan. Having two centers at a single institution is unusual and reflects Washington University's depth in structural virology and immunology.

The Coordination Layer

Research Triangle Institute (RTI) in Durham, North Carolina, serves as the centralized coordination hub. Their job is to standardize experimental design across all participating institutions through shared reagents, animal models, and datasets. This is a deliberate structural choice: NIAID wants the centers producing comparable, combinable data rather than seven siloed efforts using incompatible methods.

Each center must also establish collaboration with an industry partner providing access to manufacturing, clinical development, and regulatory expertise. This requirement reflects a hard lesson from the COVID-19 response — academic labs can identify promising candidates, but without manufacturing partners, those candidates die in the valley between discovery and deployment.

The Milestone Trap — and How to Avoid It

ReVAMPP awards are structured with a critical checkpoint near the end of year three. Recipients submit a transition package that NIAID evaluates against stated milestones. Funding for years four and five is not automatic — it depends on demonstrated progress, network contribution, and programmatic priorities.

This is not a formality. NIAID has historically been willing to restructure or terminate underperforming cooperative agreements. Investigators planning to apply for future ReVAMPP cycles should build their proposals around measurable, time-bound deliverables rather than open-ended exploration. The milestones reviewers want to see include candidate vaccine constructs entering animal studies, monoclonal antibodies with defined binding characteristics, and platform technologies validated across at least two pathogen targets.

What This Means for Researchers Not in the Network

The first round is awarded, but ReVAMPP is designed as an evolving network, not a closed club. Several pathways exist for researchers outside the initial awardees:

Subcontracts and collaborations. Each center runs multiple interdependent research projects (NIAID requires at least two but no more than five per center) plus scientific cores. Centers actively recruit collaborators with complementary expertise — particularly in areas like computational biology, structural vaccinology, and high-throughput antibody screening.

Future solicitations. NIAID has signaled that additional virus families and research priorities may be added as the network matures. Researchers working on togaviruses, coronaviruses, or other families not fully represented in the current awards should be developing preliminary data now.

Shared resources. RTI's coordination hub will maintain shared datasets and standardized reagents that, in principle, become available to qualified external investigators. Building relationships with RTI's coordination team early — before the next round — is a tactical move.

Adjacent NIH mechanisms. R01, R21, and R33 applications that reference ReVAMPP goals and propose complementary work will find receptive study sections. NIH program officers increasingly look for synergy between large cooperative agreements and investigator-initiated research.

The Budget Context

The $100 million annual commitment arrives at a moment when NIH's broader budget picture is contentious but stable. Congress locked in $48.7 billion for NIH in the FY2026 spending package — a $415 million increase over FY2025 and a bipartisan rejection of the administration's proposed 40 percent cut (Granted News). The indirect cost rate cap at 15 percent, which would have devastated university research infrastructure, remains blocked by federal courts.

Within that context, NIAID's ability to commit $100 million annually to a single program signals genuine institutional prioritization. Pandemic preparedness has durable political support that transcends the usual partisan fractures around science funding — every member of Congress remembers the supply-chain failures and vaccine timeline pressures of 2020-2021.

How to Position for the Next Round

For investigators eyeing future ReVAMPP opportunities, the playbook is clear:

Build a prototype-pathogen rationale. Frame your research around a representative pathogen whose study generates transferable knowledge across a virus family. Reviewers will look for explicit connections between your prototype and the broader family of potential pandemic threats.

Secure an industry partner. This is non-negotiable. NIAID requires established or planned collaboration with a partner that brings manufacturing, clinical development, and regulatory pathway expertise. Letters of support from pharma or biotech companies with relevant GMP capacity will strengthen any application.

Design around milestones. Structure your proposal with year-three transition milestones that are specific, measurable, and achievable. Vague promises about advancing fundamental understanding will not survive the milestone review.

Integrate computational approaches. The University of Washington's machine-learning-enabled vaccine design center signals where the field is heading. Proposals that combine wet-lab virology with computational protein engineering, AI-driven epitope prediction, or large-scale immune repertoire analysis will stand out.

Engage the coordination hub. Reach out to RTI early. Understanding the network's data standards, reagent-sharing protocols, and collaboration expectations before writing your application will give you a structural advantage.

The pandemic preparedness space is one of the few areas in federal research funding where the money, the political will, and the scientific urgency are all moving in the same direction. ReVAMPP represents the most concrete expression of that alignment — and for researchers positioned at the intersection of vaccinology, monoclonal antibody development, and emerging infectious diseases, it is the program to watch. Tools like Granted can help you track these opportunities and build a submission-ready proposal before the next funding cycle opens.